BioSpace News Archive

HUTCHMED Limited announces that it has completed patient enrollment of FRESCO-2, a Phase III registration study of fruquintinib, an investigational treatment for the treatment of patients with metastatic colorectal cancer in the U.S., Europe, Japan and Australia.

Semi-quantitative antibody testing is the molecular biology technique that quantitates particular antibodies in a sample.

The oscillating positive expiratory pressure devices are the ones which are used for clearing secretions from the airways.

Immune-mediated inflammatory disease (IMID) is a group of unrelated conditions that lack a definitive etiology, but share a common inflammatory pathway leading to inflammation.

Croup is a medical condition that refers to an infection of the upper airway, which further disrupts breathing, thereby resulting into barking cough.

Dialyzer is a type of medical device which helps in replacing the kidney function through removing metabolic waste products and excess water from the blood.

A bio-refinery plant is a facility that integrates the biomass conversion processes and equipment to produce fuels and value-added chemicals from biomass.

Bavarian Nordic A/S, a fully integrated vaccines company, announced positive topline results from a Phase 2 clinical trial of its COVID-19 vaccine candidate, ABNCoV2.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced that it will host an investor conference call and webcast tomorrow morning to discuss the topline results from the PEACE Phase 3 clinical trial of pegzilarginase in patients with Arginase 1 Deficiency.

Johnson & Johnson announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center, which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine, administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses.